《大行》高盛維持藥明生物(02269.HK)「中性」評級 目標價25.6元
高盛發表研究報告指,藥明生物(02269.HK)發盈喜,預期中期收入將按年增長約16%,符合全年增長12%至15%的指引,撇除XDC業務,核心業務增長約5%;純利料按年增長56%,略勝預期,相信來自於「R」業務里程碑收入令毛利率提升3.6個百分點、無錫XDC產能利用率提升及愛爾蘭基地虧損收窄,以及股份補償費用減少所推動的非國際財報準則淨利潤增長等綜合帶動。
高盛維持「中性」評級及目標價25.6元,預期投資者將關注ADC/XDC以外新訂單增長動能、後期及商業化項目進展以及海外產能擴張進度。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.